What is the appropriate dosing schedule for a 5‑cycle (15‑week) TCHP regimen using weekly paclitaxel and carboplatin and trastuzumab and pertuzumab administered every three weeks?

Weekly Paclitaxel and Carboplatin with Every-3-Week Trastuzumab and Pertuzumab Dosing Schedule

For a 5-cycle (15-week) TCHP regimen, administer paclitaxel 80 mg/m² IV weekly on days 1,8, and 15, carboplatin AUC 2 IV weekly on days 1,8, and 15, with trastuzumab loading dose 8 mg/kg IV followed by 6 mg/kg IV every 3 weeks, and pertuzumab loading dose 840 mg IV followed by 420 mg IV every 3 weeks, all repeated every 21 days for 5 cycles.

Detailed Dosing Algorithm

Chemotherapy Components (Weekly Administration)

• Paclitaxel: 80 mg/m² IV over 1 hour on days 1,8, and 15 of each 21-day cycle 1
• Carboplatin: AUC 2 IV over 30 minutes on days 1,8, and 15 of each 21-day cycle 1

HER2-Targeted Therapy (Every 3 Weeks)

• Trastuzumab:

  • Loading dose: 8 mg/kg IV on day 1 of cycle 1
  • Maintenance: 6 mg/kg IV every 3 weeks (on day 1 of each subsequent cycle) 2

• Pertuzumab:

  • Loading dose: 840 mg IV on day 1 of cycle 1
  • Maintenance: 420 mg IV every 3 weeks (on day 1 of each subsequent cycle)

Cycle Structure

Each cycle = 21 days (3 weeks), repeated for 5 total cycles = 15 weeks

Week-by-week breakdown:

• Weeks 1,4,7,10,13: Paclitaxel + Carboplatin + Trastuzumab + Pertuzumab (all four drugs)
• Weeks 2,5,8,11,14: Paclitaxel + Carboplatin only
• Weeks 3,6,9,12,15: Paclitaxel + Carboplatin only

Evidence Supporting This Regimen

The weekly paclitaxel/carboplatin schedule combined with every-3-week dual HER2 blockade is well-established in NCCN guidelines as a Category 1 recommendation 3. This approach offers equivalent efficacy to standard 3-weekly TCHP with significantly reduced toxicity, particularly avoiding febrile neutropenia and severe peripheral neuropathy 4, 5.

Real-world data demonstrates pCR rates of 62-77% with this weekly regimen 5, 6, comparable to standard TCHP while maintaining excellent tolerability. The regimen achieved 86% 6-month progression-free survival in metastatic settings 4 and 99% 5-year event-free survival in early-stage disease when used neoadjuvantly 7.

Critical Practical Considerations

Pertuzumab Loading Dose Management

Consider splitting the pertuzumab loading dose (420 mg on day 1, followed by 420 mg on day 8) to reduce diarrhea incidence from 60% to 40% 5. This modification does not compromise efficacy.

Dose Modifications

• Paclitaxel: Hold for ANC <1000/μL or platelets <75,000/μL; reduce to 60 mg/m² for grade 2+ neuropathy
• Carboplatin: Reduce to AUC 1.5 if platelets 50,000-75,000/μL; hold if <50,000/μL 6
• Trastuzumab/Pertuzumab: Permanently discontinue if LVEF drops >10% from baseline to <50%, or if symptomatic heart failure develops 2

Monitoring Requirements

• Cardiac: LVEF assessment at baseline, then every 3 months during treatment 1, 2
• Hematologic: CBC before each weekly dose
• Renal function: Before each carboplatin dose (affects AUC calculation)

Common Pitfalls to Avoid

1. Do not use carboplatin AUC 6 every 3 weeks with weekly paclitaxel—this dramatically increases myelosuppression risk
2. Do not delay trastuzumab/pertuzumab for neutropenia alone (only chemotherapy should be held)
3. Do not continue weekly dosing beyond week 15 without reassessment—most toxicity occurs after 12-15 weeks 5

The weekly schedule provides superior quality of life compared to 3-weekly docetaxel-based regimens, with no febrile neutropenia reported in multiple studies 4, 5, 6 and manageable diarrhea as the primary grade 3+ toxicity (8-11% incidence).